Targeting toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy. (2023). Biomolecules and Biomedicine, 688–697. https://doi.org/10.17305/bb.2023.9838